Apollomics (NASDAQ:APLM) COO Buys 20,000 Shares of Stock

Apollomics Inc. (NASDAQ:APLM) COO Yi-Kuei Chen purchased 20,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were purchased at an average price of $15.00 per share, with a total value of $300,000.00. Following the acquisition, the chief operating officer directly owned 121,248 shares in the company, valued at $1,818,720. This represents a 19.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Apollomics Stock Performance

NASDAQ:APLM traded down $0.04 during trading hours on Monday, reaching $23.36. The stock had a trading volume of 35,072 shares, compared to its average volume of 30,338. Apollomics Inc. has a 52 week low of $3.66 and a 52 week high of $42.12. The company has a 50 day moving average price of $18.24 and a two-hundred day moving average price of $17.30.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new stake in shares of Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.